Overdiagnosis in lung cancer: different perspectives, definitions, implications

Bach, Peter B.
April 2008
Thorax;Apr2008, Vol. 63 Issue 4, p298
Academic Journal
The article discusses a paper published within this issue about the implications of overdiagnosis in lung cancer.


Related Articles

  • Erlotinib and diagnostic test approved for non-small cell lung cancer.  // WHO Drug Information;2013, Vol. 27 Issue 2, p115 

    The article reports on a 2013 decision which the U.S. Food and Drug Administration made to approve the cancer drug erlotinib and the cobas EGFR Mutation Test, a test which is used to diagnose cancer.

  • Tobacco settlement leads to free cancer screening. Browne, J. Zamgba // New York Amsterdam News;08/24/2000, Vol. 91 Issue 34, p15 

    Focuses on a lung cancer diagnosis service in New York City funded by the settlement money from the tobacco industry's litigation. Amount of financing received by the diagnostic program.

  • Best strategy for NSCLC staging?  // PharmacoEconomics & Outcomes News;2/1/2013, Issue 671, p9 

    The article discusses research being done on non-small cell lung cancer (NSCLC) staging, in reference to the study "The Optimality of Different Strategies For Supplemental Staging of Non-Small-Cell Lung Cancer: A Health Economic Decision Analysis" by R. Sogaard et al., in the January 2013 issue...

  • Chinese Guidelines on the Diagnosis and Treatment of Primary Lung Cancer (2011 Version). Xiuyi Zhi; Yilong Wu; Shenglin Ma; Tianyou Wang; Changli Wang; Jie Wang; Yuankai Shi; You Lu; Lunxu Liu; Deruo Liu; Donghong Chen; Yue Yang; Xiang Du; Hong Bu; Gening Jang; Qinghua Zhou; Baohui Han; Gang Cheng; Ying Cheng; Shunchang Jiao // Chinese Journal of Lung Cancer;Dec2012, Vol. 15 Issue 12, p677 

    The article is in foreign language.

  • Treatment for advanced NSCLC no longer a one-size-fits-all approach. Shafer, Emily // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p1 

    The article discusses a paradigm shift in diagnosis and treatment of non-small-cell lung carcinoma (NSCLC) wherein several practice-changing studies regarding treatment of NSCLC have emerged such as the inclusion of bevacizumab in the treatment of non-squamous NSCLC.

  • Correction: Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and NLST Cohorts. null, null // PLoS Medicine;Jan2015, Vol. 12 Issue 1, p1 

    A correction to the article "Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and NLST Cohorts" that was published in the 2014 issue is presented.

  • Reliability of node size as an indicator of benign status. Audain, Linz // American Family Physician;2/15/1997, Vol. 55 Issue 3, p964 

    Focuses on a study conducted by T. Arita, et al, published in a 1996 edition of `Chest' periodical, which reevaluated whether it was possible to reliably differentiate malignant mediastinal nodes from benign nodes by size alone and to determine the frequency of metastases to normal-sized...

  • Sweet signals. Munson, Marty; Yeykal, Teresa // Prevention;Dec95, Vol. 47 Issue 12, p34 

    Reports that a supersweet taste in your mouth is a standard symptom of cancer in your lungs. Results of case studies from `Archives of Internal Medicine' June 26, 1995 issue; Comments from study author Hercules Panayiotou. INSET: Crank the heat without getting burned..

  • Views.  // British Medical Journal (Clinical Research Edition);11/5/1983, Vol. 287 Issue 6402, p1382 

    Comments on several medical issues. Diagnosis of lung cancer during the screening of cigarette smokers; Forecast on the sales of the anticancer drug cispatinum; Preference of patients for doctors of the same sex.

  • Generalizing Lung-Cancer Screening Results.  // New England Journal of Medicine;2/16/2012, Vol. 366 Issue 7, p672 

    A correction to a letter to the editor about an article on lung cancer screening, published in the January 2012 issue is presented.


Read the Article


Sign out of this library

Other Topics